The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Unmet needs in the treatment of myelofibrosis: strategies to address anemia
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses the unmet need of treating anemia in patients with myelofibrosis. Prof. Rinaldi notes the limitations of current treatment options and advises that switching JAK inhibitors could be effective in certain patients. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
